DRG SARS-CoV-2 (RBD) IgG ELISA
DRG SARS-CoV-2 (RBD) IgG ELISA
ELISA for the quantitative and highly specific detection of human IgG antibodies against Coronavirus SARS-CoV-2 in human serum and plasma.
Benefits at a Glance:
- Tests detect neutralizing antibodies directed against Receptor Binding
- Domain (RBD) of spike protein of SARS-CoV-2 High specificity and sensitivity Results in 105 (IgG) minutes
- Ready-to-use reagents included
- Tests are prepared for automation on open ELISA platforms
- Developed, validated and manufactured in Marburg, Germany
- EU: CE / IVD
Intended Use of DRG SARS-CoV-2 Antibody ELISAs
SARS-CoV-2 (RBD) IgG ELISA – EIA-6150 – quantitative
- Detection of prior virus infection (> 14 days after infection)
- Monitor vaccination success
- Monitor vaccination efficiency
- Support epidemiological studies for SARS-CoV-2
Assay Principle: Indirect ELISA
Objective: Quantitative Detection of IgG in Serum and Plasma
Assay Characteristics
- Diagnostic Sensitivity: 100 % (for PCR-confirmed samples)
- Method Comparison: 100% agreement to Roche Elecsys Anti-SARS-CoV-2
- Diagnostic Specificity: 99.7 %
- Intra-Assay Precision: 3.9 – 9.1%
- Inter-Assay Precision: 8.4 – 12.0%
- Excellent Linearity of Dilution: y = 1.004+1.4; R2= 0.994
- Sample Matrix: Serum or Plasma (EDTA, lithium heparin or citrate plasma)
- Total Assay Time: 75 minutes; short hands-on time
- No dilution of samples necessary
- Negative, Cut-off and Positive Control included
- All reagents ready-to-use (except Wash Solution)
- Validated according to CLSI Guidelines
- EU: CE / IVD
- This ELISA is validated for human samples, but could also be used for veterinary applications.